Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical ...

For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...

On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...

Ebrahimi is a scientific leader at GSK. Mrksich is the Henry Wade Rogers professor at Northwestern University, where he is developing the MegaMolecule technology for creating multifunctional ...

The wide range of chromatographic techniques share one common aim: to separate a material into its components. A material, your sample, is dissolved in a solvent, called the mobile phase. This mixture ...

BUFFALO, N.Y. — University at Buffalo researcher Murali Ramanathan, PhD, has used artificial intelligence (AI) since its nascent days while exploring possible treatments for multiple sclerosis (MS) ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

As drug costs rise and public trust falls, A.I. may transform the economics of clinical trials—and reshape the future of pharma. Unsplash+ Sixty percent of the total U.S. population takes at least one ...

I volunteered to participate in a Phase 2 clinical trial to test a treatment for dengue fever. This is what I learned in my time as a human test subject. Credit: Max Barnhart/Aislinn Woody/Madeline ...